Lantern Pharma, Inc. (LTRN)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Apr 21, 2025

$3.11

P/E Ratio

N/A

Market Cap

$33.54M

Description
Add to research
View more

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Metrics
Add to research
View more

Overview

  • HQDallas, TX
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerLTRN
  • Price$3.11-9.06%

Trading Information

  • Market cap$33.54M
  • Float74.47%
  • Average Daily Volume (1m)43,257
  • Average Daily Volume (3m)81,519
  • EPS-$1.93

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$20.78M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$22.03M
  • EV$10.56M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B1.58
  • Debt/Equity1.15
Documents
Add to research
View more